As many as 40% of cancer patients receiving immune checkpoint inhibitors experience immune-related adverse events.
HealthDay News — COVID-19 is associated with long-term risk for autoimmune and autoinflammatory connective tissue disorders, according to a study published online Nov. 6 in JAMA Dermatology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback